Clinical Trials Logo

Olfactory Disorder clinical trials

View clinical trials related to Olfactory Disorder.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05542095 Withdrawn - COVID-19 Clinical Trials

Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia

SimCA
Start date: May 1, 2023
Phase: Phase 1
Study type: Interventional

Olfactory dysfunction (OD) or changes in smell and/or taste is one of the cardinal presenting symptoms of COVID-19. Despite the prevalence of COVID and resultant OD, the pathophysiology of COVID-mediated OD is not fully understood, but recent evidence indicates that local inflammatory and oxidative injury play a major role. This phase 1 safety trial evaluates the use of simvastatin nasal irrigations for the management of COVID-mediated OD. We will determine the maximum tolerable dose and evaluate the safety and tolerability of high-volume simvastatin nasal irrigations in subjects with persistent COVID-mediated OD. Each subject will complete bloodwork at baseline and then at the completion of their participation in the study. During this trial, we will observe olfactory function for each participant at baseline and completion of this study via the University of Pennsylvania Smell Identification Test (UPSIT). Investigational product will be shipped directly to the subject for daily irrigation each day for 4 weeks. Weekly throughout the study for a total of 4 weeks, subjects will complete the Sino-Nasal Outcome Test-22. The current study would provide the support for Phase II and III clinical trials. Additionally, the study has applications for other disease processes affecting the sinonasal cavities.

NCT ID: NCT05216614 Withdrawn - COVID-19 Clinical Trials

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

FluCOP
Start date: December 14, 2021
Phase: Phase 2
Study type: Interventional

This study will investigate the efficacy of oral fluvoxamine in olfactory improvement following Covid-19- associated parosmia. This is a randomized, double-blinded, placebo-controlled trial.

NCT ID: NCT04374474 Withdrawn - Olfactory Disorder Clinical Trials

Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)

Start date: January 10, 2021
Phase: Phase 4
Study type: Interventional

The study will be a randomized controlled trial, involving patients with hyposmia/anosmia of onset immediately after an upper respiratory viral illness, assigned to three distinct study arms. Nasal irrigations will be prescribed to all three groups (BID). In addition, one arm will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care) and act as a control group. The second group will receive an essential oil retraining kit, whereas the third group will receive the same olfactory training kit and a prescription to use budesonide with the nasal irrigations. Olfactory scores will be tested at the enrollment, 3 months and at 6 months.